IMDX

Insight Molecular Diagnostic

-$62.8M

Net Activity

Institutions Holding

41

Popularity Rank

#6495

Avg Weight

0.62%

Total Value

$62.1M

Ownership Trend

41 institutions currently hold IMDX, with 25 net buyers and 13 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Majority Increased

Based on recent trading activity

Net Selling Institutions

13

Net Buying Institutions

25

Key Holders

View all 41 holding institutions

Quarterly Activity

Recent Activity

+$47.1M

Total Buy Value

$23.6M

Total Sell Value

New buy14
Trim6
Add11
Sold out7

25

Net Buyers

13

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding INSIGHT MOLECULAR DIAGNOSTIC (IMDX)?
Major stakeholders currently include Broadwood Capital INC ($39.1M), AWM Investment Company, Inc. ($9.2M), Pura Vida Investments, LLC ($3.1M). Based on the latest 13F filings, there are a total of 41 tracked investment funds and institutions maintaining positions in IMDX.
What is the overall institutional sentiment toward IMDX recently?
Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $62.8M, driven by 25 managers accumulating shares while 13 reduced their exposure.
Which institutions have been selling or reducing their IMDX positions?
In the latest period, 6 funds trimmed their holdings, and 7 managers completely exited their positions. The aggregate reported sell value was $23.6M.
Are there any notable investors adding IMDX to their portfolios?
Yes, buying activity remains notable. 14 institutions opened new positions in {ticker}, and 11 existing holders added to their shares. The total reported buy value for the quarter amounted to $47.1M.

Related Stocks